|
Oct 9
|
Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
|
|
Oct 9
|
Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales
|
|
Oct 7
|
Exploring 3 High Growth Tech Stocks in the United States
|
|
Sep 5
|
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|
|
Sep 4
|
High Growth Tech Stocks To Watch In September 2024
|
|
Jul 25
|
Travere Therapeutics to Report Second Quarter 2024 Financial Results
|
|
Jun 18
|
Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago
|
|
May 9
|
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
|
|
May 8
|
Travere Therapeutics to Present at Upcoming Investor Conferences
|
|
May 8
|
Loss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-Term
|
|
May 7
|
Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...
|
|
May 6
|
Travere Therapeutics Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
Travere Therapeutics to Report First Quarter 2024 Financial Results
|
|
Apr 24
|
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
|
Apr 24
|
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
|
|
Apr 4
|
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
|
|
Apr 3
|
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
|
|
Mar 13
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 11
|
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
|
|
Dec 4
|
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
|